An encouraging progress report on the treatment of progeria and its implications for atherogenesis.
Oshima, Junko; Hisama, Fuki M; Martin, George M.
; 130(1): 4-6, 2014 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-24795391
Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome.
Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome.
Progeria: a paradigm for translational medicine.
Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome.
Blocking protein farnesylation improves nuclear shape abnormalities in keratinocytes of mice expressing the prelamin A variant in Hutchinson-Gilford progeria syndrome.
Drug development for progeria yields insights into normal aging.
Induced pluripotent stem cells reveal functional differences between drugs currently investigated in patients with hutchinson-gilford progeria syndrome.
Prelamin A prenylation and the treatment of progeria.
The posttranslational processing of prelamin A and disease.
The bisphosphonate zoledronic acid effectively targets lung cancer cells by inhibition of protein prenylation.